As­traZeneca, Dai­ichi Sankyo’s En­her­tu im­press­es in 'game-chang­ing' study with many can­cers: #AS­CO23

CHICA­GO — As­traZeneca and Dai­ichi Sankyo’s En­her­tu showed promis­ing ef­fi­ca­cy in a range of can­cers — par­tic­u­lar­ly gy­ne­co­log­ic can­cers — that ex­press the bio­mark­er HER2, ac­cord­ing to a study re­leased at AS­CO’s an­nu­al meet­ing on Mon­day.

The Phase II, open-la­bel tri­al could pave the way for En­her­tu for a num­ber of new in­di­ca­tions down the line, such as en­dome­tri­al and cer­vi­cal can­cers, and in can­cers where HER2 test­ing is not the norm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER